PDF(Pubmed)
Abstract：
As the clinical applications of immune checkpoint inhibitors (ICIs) expand, our knowledge of the potential adverse effects of these drugs continues to broaden. Emerging evidence supports the association between ICI therapy with accelerated atherosclerosis and atherosclerotic cardiovascular (CV) events. We discuss the biological plausibility and the clinical evidence supporting an effect of inhibition of these immune checkpoints on atherosclerotic CV disease. Further, we provide a perspective on potential diagnostic and pharmacological strategies to reduce atherosclerotic risk in ICI-treated patients. Our understanding of the pathophysiology of ICI-related atherosclerosis is in its early stages. Further research is needed to identify the mechanisms linking ICI therapy to atherosclerosis, leverage the insight that ICI therapy provides into CV biology, and develop robust approaches to manage the expanding cohort of patients who may be at risk for atherosclerotic CV disease.
摘要：
随着免疫检查点抑制剂(ICIs)临床应用的扩大，我们对这些药物潜在不良反应的认识不断拓宽.新的证据支持ICI治疗与加速的动脉粥样硬化和动脉粥样硬化心血管（CV）事件之间的关联。我们讨论了生物学上的合理性和支持抑制这些免疫检查点对动脉粥样硬化性CV疾病的影响的临床证据。Further,我们提供了在ICI治疗患者中降低动脉粥样硬化风险的潜在诊断和药理学策略的观点.我们对ICI相关动脉粥样硬化的病理生理学的理解尚处于早期阶段。需要进一步的研究来确定将ICI治疗与动脉粥样硬化联系起来的机制，利用ICI疗法为CV生物学提供的洞察力，并开发稳健的方法来管理可能有动脉粥样硬化性CV疾病风险的患者队列。
